In Helvetic BioPharma we believe that a strong and qualified R&D team is at the base of a winning strategy for the growth of the company and it will contribute to our future product portfolio.


That’s why Helvetic BioPharma is always adapting to new opportunities and challenges investing in R&D especially in the field of slow release drugs that are rapidly improving the quality of medicines for specific diseases.
We aim to develop medicines that are differentiated for their therapeutic value and supported by compelling health economic evidence.